← Back to Search

Anti-metabolites

Treatment (docetaxel, capecitabine) for Head and Neck Squamous Cell Carcinoma

Phase 2
Waitlist Available
Led By Apar Ganti, MD
Research Sponsored by University of Nebraska
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first date of therapy until the date of death from any cause, assessed up to 5 years
Awards & highlights

Summary

This trial is testing a combination of two drugs to treat patients with squamous cell carcinoma of the head and neck that has returned or spread.

Eligible Conditions
  • Head and Neck Squamous Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first date of therapy until the date of death from any cause, assessed up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and first date of therapy until the date of death from any cause, assessed up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Response Rate of Complete or Partial Response
Secondary study objectives
Progression-free Survival
Survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (docetaxel, capecitabine)Experimental Treatment4 Interventions
Patients receive docetaxel IV over 1 hour on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Capecitabine
2013
Completed Phase 3
~3970
Docetaxel
1995
Completed Phase 4
~5620

Find a Location

Who is running the clinical trial?

University of NebraskaLead Sponsor
554 Previous Clinical Trials
1,145,422 Total Patients Enrolled
Apar Ganti, MDPrincipal InvestigatorUniversity of Nebraska
2 Previous Clinical Trials
23 Total Patients Enrolled
Apar GantiPrincipal InvestigatorUniversity of Nebraska
2 Previous Clinical Trials
42 Total Patients Enrolled
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top